APOE and Alzheimer’s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction
Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for late onset Alzheimer’s Disease (AD), and is associated with impairments in cerebral metabolism and cerebrovascular function. A substantial body of literature now points to E4 as a driver of multiple impairments seen in AD, including...
Main Authors: | Jason A. Brandon, Brandon C. Farmer, Holden C. Williams, Lance A. Johnson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-06-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2018.00180/full |
Similar Items
-
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
by: Sheina Emrani, et al.
Published: (2020-11-01) -
ApoE4: an emerging therapeutic target for Alzheimer’s disease
by: Mirna Safieh, et al.
Published: (2019-03-01) -
Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model
by: Tien-Phat V. Huynh, et al.
Published: (2019-10-01) -
Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer’s Disease
by: Xin Zhang, et al.
Published: (2023-01-01) -
The Endosomal–Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo
by: Tal Nuriel, et al.
Published: (2017-12-01)